logo-loader
RNS
Allergan

BlackRock Group - Form 8.3 - Allergan PLC

RNS Number : 3545M
BlackRock Group
11 May 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

BlackRock, Inc.

Company dealt in

Allergan plc

Class of relevant security to which the dealings being disclosed relate 2)

US$0.0001 ordinary shares

Date of dealing

07 May 2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)


Long

Short


Number


(%)

Number


(%)

(1) Relevant securities

21,223,487 (6.44%)

42,492 (0.01%)

(2) Derivatives (other than options)

4,501,689 (1.36%)

36,763 (0.01%)

(3) Options and agreements to purchase/sell

0 (0.00%)

0 (0.00%)

Total

25,725,176 (7.81%)

79,255 (0.02%)

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short


Number


(%)

Number


(%)

(1) Relevant securities



 

(2) Derivatives (other than options)



 

(3) Options and agreements to purchase/sell



Total




Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

10,398

USD 192.9900

Purchase

3,231

USD 193.1896

Purchase

28

USD 193.3686

Purchase

1,147

USD 193.5138

Purchase

322

USD 193.7362

Purchase

500

USD 193.8900

Purchase

1,010

USD 194.2508

Sale

8,865

USD 192.9900

Sale

1,512

USD 193.8260

Sale

5,300

USD 193.8900

   

Please note: there was also a Transfer Out of 4,383 Shares

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

CFD

Increasing Short

4,799

USD 193.2306

TR Swap

Reducing Long

3,408

N/A

 

TR Swap

Reducing Long

3,839

N/A

 

TR Swap

Reducing Long

1,664

N/A

 

TR Swap

Reducing Long

1,910

N/A

 

TR Swap

Reducing Long

3,650

N/A

   

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit 5)




 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)




   


Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

None

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                    NO

 

Date of disclosure

08 May 2020

Contact name

Jana Blumenstein

Telephone number

+44 20 7743 3650

a connected EFM, name of offeree/offeror with which connected


If a connected EFM, state nature of connection (Note 10)


 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEUPUWWAUPUGGR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read